Skip to content
Global Locations
Contact Us
Search
About Us
History
Leadership
Global Locations
What We Treat
Eye Care :
Dry Eye
Glaucoma
Other Eye Conditions
Neurosciences :
Blepharospasm
Cervical Dystonia
Strabismus
Upper Limb Spasticity
Obesity Intervention
Medical Aesthetics :
Breast Aesthetics
Facial Aesthetics
Medical Dermatology :
Acne
Psoriasis
Severe Primary Axillary Hyperhidrosis Inadequately Managed with Topical Agents
Other Skin Conditions
Urologics :
Overactive Bladder
Products
Ophthalmic Pharmaceuticals
Neurosciences
Obesity Intervention
Medical Aesthetics: Breast and Facial
Medical Dermatology
Urologics
Product Prescribing and Labeling Information
R&D
Pipeline
Corporate Research Collaborations
Allergan Clinical Trials
Excellence in Research
Newsroom
Fast Facts
Press Releases
Investors
Earnings Releases
Stock Information
Financial Reports
Non-GAAP Financial Reconciliation
Corporate Governance & Certificates
Webcasts & Transcripts
Analyst Coverage
Shareholder Information
Contact Information
Responsibility
Patient Safety and Product Quality
Allergan Foundation
Patient Resources
Physician Resources
Professional Affiliations
Unrestricted Educational Grants
Political Contributions
Compliance
California Supply Chain Disclosure
Health Care Provider Partnerships & Payments
Commitment to Human Rights Charters
Environmental Health and Safety
Animal Testing
Careers
Culture
Benefits
Recognizing Excellence
Job Search
My Candidate Profile
FAQ
-->-->-->-->
In this Section:
Overview
Pipeline
Corporate Research Collaborations
Allergan Clinical Trials
Excellence in Research
Related Links:
Allerganclinicaltrials.com
Pipeline
Ophthalmics
Product
Indication
Industry Partners
Status
OZURDEX
®
Diabetic Macular Edema
-
Phase 3
RESTASIS
®
(Europe)
Ocular Surface Disease
-
Phase 3
RESTASIS
®
X
Ocular Surface Disease
-
Phase 2
IOP Lowering (EP Agonist)
Glaucoma
-
Phase 2
IOP Lowering (Sustained Release)
Glaucoma
-
Phase 2
NOVADUR
®
(Brimonidine)
Retinal Diseases
-
Phase 2
DARPin Anti-VEGF
Age-Related Macular Degeneration
-
Phase 2
TKI
Age-Related Macular Degeneration
-
Pre-Clinical
Neurology
Product
Indication
Industry Partners
Status
LEVADEX
®
Migraine (Acute Therapy)
MAP Pharmaceuticals, Inc.
Filed
BOTOX
®
(U.S.)
Juvenile Cerebral Palsy
-
Phase 2
Targeted Toxin
Pain
-
Phase 2
Pharmaceutical Dermatology
Product
Indication
Industry Partners
Status
LATISSE
®
(EU)
Lash
-
Filed
LATISSE
®
Brow
-
Phase 2
Bimatoprost
Scalp
-
Phase 2
Vicept V-101
Rosacea
-
Phase 2
Urology
Product
Indication
Industry Partners
Status
BOTOX
®
Overactive Bladder - Idiopathic
-
Phase 3
BOTOX
®
Benign Prostatic Hyperplasia
-
Phase 2
Targeted Toxin
Overactive Bladder
-
Phase 2
SER-120
Nocturia
Serenity Pharmaceuticals, LLC
Phase 3
Apaziquone
Bladder Cancer
Spectrum Pharmaceuticals, Inc.
Phase 3
Medical Devices (Health/Aesthetics)
Product
Indication
Industry Partners
Status
Silicone Breast – Style 410 Cohesive Gel
Breast Reconstruction/Augmentation
-
Filed
ORBERA™ (U.S.)
Obesity
-
Clinical
JUVÉDERM
®
VOLUMA™ (U.S.)
Facial Aesthetics
-
Filed
Research Centers of Excellence
Allergan's R&D facilities contain state-of-the-art laboratories to support early stage, leading-edge discovery research. They include specialized areas for molecular biology, neuromodulator research, high throughput screening and medicinal chemistry. In 2004, we opened the Herbert Research Center (pictured above) to accommodate the tremendous growth of our new drug discovery programs, and to enhance our ability to more rapidly move new medicines into the clinic that satisfy unmet medical needs and enable patients to live life to its fullest potential.